

EVITRADE ANNOUNCES REBRANDING AND NAME CHANGE TO THERAMED HEALTH CORPORATION

VANCOUVER, BC, Tuesday, May 7, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “**Company**”) is pleased to announce that on May 1, 2019 it changed its name from “EVITRADE Health Systems Corp.” to “THERAMED HEALTH CORPORATION” with the British Columbia corporate registry, and it has rebranded itself under its new name and will trade under the new symbol “**TMED**” expected to be effective May 8, 2019.

The Company has filed its Change of Corporate Structure and certificate of name change on www.SEDAR.com in conjunction with the rebranding. The Company’s new CUSIP is “88339L100” and its new ISIN is “CA88339L1004”.

Corporate Update

The Company is continuing work on developing products, research, and commercialization on several fronts including but not limited to:

- Continued development under its previously announced joint-venture for its licensed excipient delivery system that includes formulation of Hemp-based (CBD) and other nutraceuticals/pharmaceuticals.
- Setup and production of CBD using proprietary extraction technologies at its facility in Nevada.
- Developing CBD protocols and research – focused on achieving elevation of the human condition through advanced medical solutions and effective health and wellness products.
- Personalized medical care system (including CBD usage monitoring and effects on the cardiovascular system) in addition to advanced molecular biology.

THERAMED HEALTH CORPORATION

Email theramedhealthcorp@gmail.com

Website <http://www.theramed.ca> <http://www.theramedhealthcorp.com> (both currently under construction) <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

About THERAMED HEALTH

(CSE: TMED, OTCQB: EVAHF)

Theramed Health Corporation – is a technology company specializing in the Health and Life Sciences sector looking to deliver effective personalized health solutions and products with a higher degree of predictability and consistency.

The Company is focused on the following areas to help improve health: personalized medical care (including CBD usage monitoring and effects on the cardiovascular system), molecular biology, pharmaceutical & nutraceutical solutions, and genetics.

Through its subsidiaries' focus on technologies involved in extracting and purifying CBD extracts for its personalized healthcare system, the Company may be the first to offer a complete quality assured vertically integrated “CBD Health System” for monitoring and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.